

26. (New) The fusion polypeptide of claim 25, wherein said second polypeptide comprises an Fc region of an immunoglobulin heavy chain.

DI 27. (New) A method for treating a hyperacute rejection reaction in a subject in need thereof, the method comprising withdrawal of plasma from the subject, bringing said plasma in contact with the fusion polypeptide of claim 21 to couple anti-pig antibodies thereto and thereafter reinfusing said plasma to said subject.

28. (New) The fusion protein of claim 21, wherein the first polypeptide comprises more Gal α 1, 3Gal epitopes than a wild-type P-selectin glycoprotein ligand-1 polypeptide.

REMARKS

Upon entry of the foregoing amendments, claims 21-28 are under consideration.

New claim 21 is supported in the specification, *e.g.* page 4, lines 11-22 page 4, line 34 to page 5, line 5, page 5, lines 26-34, and originally filed claims 1, 4 and 9. Specifically, support for the fusion polypeptide as a dimer can be found in the specification, *e.g.*, page 4, lines 29-30, page 11, lines 23-25, and Figure 1 (substitute sheet). New claim 22 is supported in the specification, *e.g.* page 4, lines 9-10, and by original claim 1. New claim 23 is supported in the specification, *e.g.* page 4, lines 20-22, and original claim 4. New claim 24 is supported in the specification, *e.g.* page 5, lines 6-9 and by original claim 8. New claim 25 is supported in the specification, *e.g.* page 5, lines 26-34, and by original claim 9. New claim 26 is supported in the specification, *e.g.* page 5, lines 36-38, and by original claim 10. New claim 27 is supported in the specification, *e.g.* page 7, lines 1-13, and by original claim 20. Support for new claim 28 appears in the specification, *e.g.* page 4, line 27-29. Thus, these amendments add no new matter.

Version With Markings to Show Changes

Claims 1-6, 8, 10-14, and 20 were canceled and replaced with new claims 21-28.

CONCLUSION

On the basis of the foregoing amendments, Applicants respectfully submit that the pending claims are in condition for allowance. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact either of the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Cynthia A. Kozakiewicz, Reg. No. 42,764
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

DATED: August 28, 2001